Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.

Individuals with high intensity of Loa loa are at risk of developing serious adverse events (SAEs) post treatment with ivermectin. These SAEs have remained unclear and a programmatic impediment to the advancement of community directed treatment with ivermectin. The pathogenesis of these SAEs followi...

Full description

Bibliographic Details
Main Authors: Samuel Wanji, Ebanga-Echi J Eyong, Nicholas Tendongfor, Che J Ngwa, Elive N Esuka, Arnaud J Kengne-Ouafo, Fabrice R Datchoua-Poutcheu, Peter Enyong, Dalen Agnew, Rob R Eversole, Adrian Hopkins, Charles D Mackenzie
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-07-01
Series:PLoS Neglected Tropical Diseases
Online Access:http://europepmc.org/articles/PMC5533442?pdf=render
_version_ 1818639973954355200
author Samuel Wanji
Ebanga-Echi J Eyong
Nicholas Tendongfor
Che J Ngwa
Elive N Esuka
Arnaud J Kengne-Ouafo
Fabrice R Datchoua-Poutcheu
Peter Enyong
Dalen Agnew
Rob R Eversole
Adrian Hopkins
Charles D Mackenzie
author_facet Samuel Wanji
Ebanga-Echi J Eyong
Nicholas Tendongfor
Che J Ngwa
Elive N Esuka
Arnaud J Kengne-Ouafo
Fabrice R Datchoua-Poutcheu
Peter Enyong
Dalen Agnew
Rob R Eversole
Adrian Hopkins
Charles D Mackenzie
author_sort Samuel Wanji
collection DOAJ
description Individuals with high intensity of Loa loa are at risk of developing serious adverse events (SAEs) post treatment with ivermectin. These SAEs have remained unclear and a programmatic impediment to the advancement of community directed treatment with ivermectin. The pathogenesis of these SAEs following ivermectin has never been investigated experimentally. The Loa/baboon (Papio anubis) model can be used to investigate the pathogenesis of Loa-associated encephalopathy following ivermectin treatment in humans.12 baboons with microfilarial loads > 8,000mf/mL of blood were randomised into four groups: Group 1 (control group receiving no drug), Group 2 receiving ivermectin (IVM) alone, Group 3 receiving ivermectin plus aspirin (IVM + ASA), and Group 4 receiving ivermectin plus prednisone (IVM + PSE). Blood samples collected before treatment and at Day 5, 7 or 10 post treatment, were analysed for parasitological, hematological and biochemical parameters using standard techniques. Clinical monitoring of animals for side effects took place every 6 hours post treatment until autopsy. At autopsy free fluids and a large number of standard organs were collected, examined and tissues fixed in 10% buffered formalin and processed for standard haematoxylin-eosin staining and specific immunocytochemical staining.Mf counts dropped significantly (p<0.05) in all animals following ivermectin treatment with reductions as high as (89.9%) recorded; while no significant drop was observed in the control animals. Apart from haemoglobin (Hb) levels which recorded a significant (p = 0.028) drop post treatment, all other haematological and biochemical parameters did not show any significant changes (p>0.05). All animals became withdrawn 48 hours after IVM administration. All treated animals recorded clinical manifestations including rashes, itching, diarrhoea, conjunctival haemorrhages, lymph node enlargement, pinkish ears, swollen face and restlessness; one animal died 5 hours after IVM administration. Macroscopic changes in post-mortem tissues observed comprised haemorrhages in the brain, lungs, heart, which seen in all groups given ivermectin but not in the untreated animals. Microscopically, the major cellular changes seen, which were present in all the ivermectin treated animals included microfilariae in varying degrees of degeneration in small vessels. These were frequently associated with fibrin deposition, endothelial changes including damage to the integrity of the blood vessel and the presence of extravascular erythrocytes (haemorrhages). There was an increased presence of eosinophils and other chronic inflammatory types in certain tissues and organs, often in large numbers and associated with microfilarial destruction. Highly vascularized organs like the brain, heart, lungs and kidneys were observed to have more microfilariae in tissue sections. The number of mf seen in the brain and kidneys of animals administered IVM alone tripled that of control animals. Co-administration of IVM + PSE caused a greater increase in mf in the brain and kidneys while the reverse was noticed with the co-administration of IVM + ASA.The treatment of Loa hyper-microfilaraemic individuals with ivermectin produces a clinical spectrum that parallels that seen in Loa hyper-microfilaraemic humans treated with ivermectin. The utilization of this experimental model can contribute to the improved management of the adverse responses in humans.
first_indexed 2024-12-16T23:03:53Z
format Article
id doaj.art-25132ac626e843719e0e99916770d433
institution Directory Open Access Journal
issn 1935-2727
1935-2735
language English
last_indexed 2024-12-16T23:03:53Z
publishDate 2017-07-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Neglected Tropical Diseases
spelling doaj.art-25132ac626e843719e0e99916770d4332022-12-21T22:12:38ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352017-07-01117e000557610.1371/journal.pntd.0005576Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.Samuel WanjiEbanga-Echi J EyongNicholas TendongforChe J NgwaElive N EsukaArnaud J Kengne-OuafoFabrice R Datchoua-PoutcheuPeter EnyongDalen AgnewRob R EversoleAdrian HopkinsCharles D MackenzieIndividuals with high intensity of Loa loa are at risk of developing serious adverse events (SAEs) post treatment with ivermectin. These SAEs have remained unclear and a programmatic impediment to the advancement of community directed treatment with ivermectin. The pathogenesis of these SAEs following ivermectin has never been investigated experimentally. The Loa/baboon (Papio anubis) model can be used to investigate the pathogenesis of Loa-associated encephalopathy following ivermectin treatment in humans.12 baboons with microfilarial loads > 8,000mf/mL of blood were randomised into four groups: Group 1 (control group receiving no drug), Group 2 receiving ivermectin (IVM) alone, Group 3 receiving ivermectin plus aspirin (IVM + ASA), and Group 4 receiving ivermectin plus prednisone (IVM + PSE). Blood samples collected before treatment and at Day 5, 7 or 10 post treatment, were analysed for parasitological, hematological and biochemical parameters using standard techniques. Clinical monitoring of animals for side effects took place every 6 hours post treatment until autopsy. At autopsy free fluids and a large number of standard organs were collected, examined and tissues fixed in 10% buffered formalin and processed for standard haematoxylin-eosin staining and specific immunocytochemical staining.Mf counts dropped significantly (p<0.05) in all animals following ivermectin treatment with reductions as high as (89.9%) recorded; while no significant drop was observed in the control animals. Apart from haemoglobin (Hb) levels which recorded a significant (p = 0.028) drop post treatment, all other haematological and biochemical parameters did not show any significant changes (p>0.05). All animals became withdrawn 48 hours after IVM administration. All treated animals recorded clinical manifestations including rashes, itching, diarrhoea, conjunctival haemorrhages, lymph node enlargement, pinkish ears, swollen face and restlessness; one animal died 5 hours after IVM administration. Macroscopic changes in post-mortem tissues observed comprised haemorrhages in the brain, lungs, heart, which seen in all groups given ivermectin but not in the untreated animals. Microscopically, the major cellular changes seen, which were present in all the ivermectin treated animals included microfilariae in varying degrees of degeneration in small vessels. These were frequently associated with fibrin deposition, endothelial changes including damage to the integrity of the blood vessel and the presence of extravascular erythrocytes (haemorrhages). There was an increased presence of eosinophils and other chronic inflammatory types in certain tissues and organs, often in large numbers and associated with microfilarial destruction. Highly vascularized organs like the brain, heart, lungs and kidneys were observed to have more microfilariae in tissue sections. The number of mf seen in the brain and kidneys of animals administered IVM alone tripled that of control animals. Co-administration of IVM + PSE caused a greater increase in mf in the brain and kidneys while the reverse was noticed with the co-administration of IVM + ASA.The treatment of Loa hyper-microfilaraemic individuals with ivermectin produces a clinical spectrum that parallels that seen in Loa hyper-microfilaraemic humans treated with ivermectin. The utilization of this experimental model can contribute to the improved management of the adverse responses in humans.http://europepmc.org/articles/PMC5533442?pdf=render
spellingShingle Samuel Wanji
Ebanga-Echi J Eyong
Nicholas Tendongfor
Che J Ngwa
Elive N Esuka
Arnaud J Kengne-Ouafo
Fabrice R Datchoua-Poutcheu
Peter Enyong
Dalen Agnew
Rob R Eversole
Adrian Hopkins
Charles D Mackenzie
Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.
PLoS Neglected Tropical Diseases
title Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.
title_full Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.
title_fullStr Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.
title_full_unstemmed Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.
title_short Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.
title_sort ivermectin treatment of loa loa hyper microfilaraemic baboons papio anubis assessment of microfilarial load reduction haematological and biochemical parameters and histopathological changes following treatment
url http://europepmc.org/articles/PMC5533442?pdf=render
work_keys_str_mv AT samuelwanji ivermectintreatmentofloaloahypermicrofilaraemicbaboonspapioanubisassessmentofmicrofilarialloadreductionhaematologicalandbiochemicalparametersandhistopathologicalchangesfollowingtreatment
AT ebangaechijeyong ivermectintreatmentofloaloahypermicrofilaraemicbaboonspapioanubisassessmentofmicrofilarialloadreductionhaematologicalandbiochemicalparametersandhistopathologicalchangesfollowingtreatment
AT nicholastendongfor ivermectintreatmentofloaloahypermicrofilaraemicbaboonspapioanubisassessmentofmicrofilarialloadreductionhaematologicalandbiochemicalparametersandhistopathologicalchangesfollowingtreatment
AT chejngwa ivermectintreatmentofloaloahypermicrofilaraemicbaboonspapioanubisassessmentofmicrofilarialloadreductionhaematologicalandbiochemicalparametersandhistopathologicalchangesfollowingtreatment
AT elivenesuka ivermectintreatmentofloaloahypermicrofilaraemicbaboonspapioanubisassessmentofmicrofilarialloadreductionhaematologicalandbiochemicalparametersandhistopathologicalchangesfollowingtreatment
AT arnaudjkengneouafo ivermectintreatmentofloaloahypermicrofilaraemicbaboonspapioanubisassessmentofmicrofilarialloadreductionhaematologicalandbiochemicalparametersandhistopathologicalchangesfollowingtreatment
AT fabricerdatchouapoutcheu ivermectintreatmentofloaloahypermicrofilaraemicbaboonspapioanubisassessmentofmicrofilarialloadreductionhaematologicalandbiochemicalparametersandhistopathologicalchangesfollowingtreatment
AT peterenyong ivermectintreatmentofloaloahypermicrofilaraemicbaboonspapioanubisassessmentofmicrofilarialloadreductionhaematologicalandbiochemicalparametersandhistopathologicalchangesfollowingtreatment
AT dalenagnew ivermectintreatmentofloaloahypermicrofilaraemicbaboonspapioanubisassessmentofmicrofilarialloadreductionhaematologicalandbiochemicalparametersandhistopathologicalchangesfollowingtreatment
AT robreversole ivermectintreatmentofloaloahypermicrofilaraemicbaboonspapioanubisassessmentofmicrofilarialloadreductionhaematologicalandbiochemicalparametersandhistopathologicalchangesfollowingtreatment
AT adrianhopkins ivermectintreatmentofloaloahypermicrofilaraemicbaboonspapioanubisassessmentofmicrofilarialloadreductionhaematologicalandbiochemicalparametersandhistopathologicalchangesfollowingtreatment
AT charlesdmackenzie ivermectintreatmentofloaloahypermicrofilaraemicbaboonspapioanubisassessmentofmicrofilarialloadreductionhaematologicalandbiochemicalparametersandhistopathologicalchangesfollowingtreatment